Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 20

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Solution structure and binding specificity of the p63 DNA binding domain

Enthart, Andreas, Klein, Christian, Dehner, Alexander, Coles, Murray, Gemmecker, Gerd, Kessler, Horst, Hagn, Franz·2016·Scientific Reports
DOI 10.1038/srep26707
Open this paper in CoChat — free account

Abstract

p63 is a close homologue of p53 and, together with p73, is grouped into the p53 family of transcription factors. p63 is known to be involved in the induction of controlled apoptosis important for differentiation processes, germ line integrity and development. Despite its high homology to p53, especially within the DNA binding domain (DBD), p63-DBD does not show cooperative DNA binding properties and is significantly more stable against thermal and chemical denaturation. Here, we determined the solution structure of p63-DBD and show that it is markedly less dynamic than p53-DBD. In addition, we also investigate the effect of a double salt bridge present in p53-DBD, but not in p63-DBD on the cooperative binding behavior and specificity to various DNA sites. Restoration of the salt bridges in p63-DBD by mutagenesis leads to enhanced binding affinity to p53-specific, but not p63-specific response elements. Furthermore, we show that p63-DBD is capable of binding to anti-apoptotic BclxL via its DNA binding interface, a feature that has only been shown for p53 so far. These data suggest that all p53 family members - despite alterations in the specificity and binding affinity - are capable of activating pro-apoptotic pathways in a tissue specific manner.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep26707

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 66

  1. Lane, D. P. Cancer. p53, guardian of the genome. Nature 358, 15–16 (1992). · DOI · Paper page
  2. Romer, L., Klein, C., Dehner, A., Kessler, H. & Buchner, J. p53–a natural cancer killer: structural insights and therapeutic concepts. Angew Chem Int Ed Engl 45, 6440–6460, doi: 10.1002/anie.200600611 (2006). · DOI · Paper page
  3. Yang, A. et al. p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2, 305–316 (1998). · DOI · Paper page
  4. Kaghad, M. et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809–819 (1997). · DOI · Paper page
  5. Shimada, A. et al. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res 59, 2781–2786 (1999).
  6. Levrero, M. et al. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 113 (Pt 10), 1661–1670 (2000). · DOI · Paper page
  7. Mills, A. A. et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398, 708–713 (1999). · DOI · Paper page
  8. Yang, A., Kaghad, M., Caput, D. & McKeon, F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 18, 90–95 (2002). · DOI · Paper page
  9. Strano, S. et al. From p63 to p53 across p73. FEBS Lett 490, 163–170 (2001). · DOI
  10. Barbieri, C. E. & Pietenpol, J. A. p63 and epithelial biology. Exp Cell Res 312, 695–706 (2006). · DOI
  11. Koster, M. I. & Roop, D. R. The role of p63 in development and differentiation of the epidermis. J Dermatol Sci 34, 3–9 (2004). · DOI · Paper page
  12. Suh, E. K. et al. p63 protects the female germ line during meiotic arrest. Nature 444, 624–628, doi: 10.1038/nature05337 (2006). · DOI · Paper page
  13. McGrath, J. A. et al. Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum Mol Genet 10, 221–229 (2001). · DOI · Paper page
  14. Ianakiev, P. et al. Split-hand/split-foot malformation is caused by mutations in the p63 gene on 3q27. Am J Hum Genet 67, 59–66 (2000). · DOI · Paper page
  15. Amiel, J. et al. TP63 gene mutation in ADULT syndrome. Eur J Hum Genet 9, 642–645 (2001). · DOI
  16. Akahoshi, K., Sakazume, S., Kosaki, K., Ohashi, H. & Fukushima, Y. EEC syndrome type 3 with a heterozygous germline mutation in the P63 gene and B cell lymphoma. Am J Med Genet A 120, 370–373 (2003). · doi:10.1002/ajmg.a.20064
  17. Yang, A. et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398, 714–718 (1999). · DOI · Paper page
  18. Hagiwara, K., McMenamin, M. G., Miura, K. & Harris, C. C. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res 59, 4165–4169 (1999).
  19. Nylander, K. et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 198, 417–427 (2002). · DOI · Paper page
  20. Candi, E. et al. TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 6, 274–285 (2007). · DOI · Paper page
  21. Arrowsmith, C. H. & Morin, P. New insights into p53 function from structural studies. Oncogene 12, 1379–1385 (1996).
  22. Klein, C. et al. High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53. J Biol Chem 276, 37390–37401 (2001). · DOI
  23. Serber, Z. et al. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol 22, 8601–8611 (2002). · DOI · Paper page
  24. Chi, S. W., Ayed, A. & Arrowsmith, C. H. Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. EMBO J 18, 4438–4445 (1999). · DOI · Paper page
  25. Wang, W. K. et al. Structure of the C-terminal sterile alpha-motif (SAM) domain of human p73 alpha. Acta Crystallogr D Biol Crystallogr 57, 545–551 (2001). · DOI
  26. Pozniak, C. D. et al. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289, 304–306 (2000). · DOI · Paper page
  27. Bullock, A. N. et al. Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci USA 94, 14338–14342 (1997). · DOI · Paper page
  28. Brachmann, R. K., Yu, K., Eby, Y., Pavletich, N. P. & Boeke, J. D. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J 17, 1847–1859, doi: 10.1093/emboj/17.7.1847 (1998). · DOI · Paper page
  29. Nikolova, P. V., Wong, K. B., DeDecker, B., Henckel, J. & Fersht, A. R. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J 19, 370–378, doi: 10.1093/emboj/19.3.370 (2000). · DOI · Paper page
  30. Petty, T. J. et al. An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity. EMBO J 30, 2167–2176, doi: 10.1038/emboj.2011.127 (2011). · DOI · Paper page
  31. Nikolova, P. V., Henckel, J., Lane, D. P. & Fersht, A. R. Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci USA 95, 14675–14680 (1998). · DOI · Paper page
  32. Boeckler, F. M. et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105, 10360–10365 (2008). · DOI · Paper page
  33. Foster, B. A., Coffey, H. A., Morin, M. J. & Rastinejad, F. Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507–2510 (1999). · DOI · Paper page
  34. Chen, C., Gorlatova, N., Kelman, Z. & Herzberg, O. Structures of p63 DNA binding domain in complexes with half-site and with spacer-containing full response elements. Proc Natl Acad Sci USA 108, 6456–6461 (2011). · DOI
  35. Chen, C., Gorlatova, N. & Herzberg, O. Pliable DNA conformation of response elements bound to transcription factor p63. J Biol Chem 287, 7477–7486, doi: 10.1074/jbc.M111.315820 (2012). · DOI
  36. Furrer, J. et al. Backbone 1H, 13C and 15N resonance assignments for the 25.8 kDa DNA binding domain of the human p63 protein. J Biomol NMR 26, 377–378 (2003). · DOI
  37. DeYoung, M. P. et al. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res 66, 9362–9368 (2006). · DOI
  38. Dehner, A. et al. Cooperative binding of p53 to DNA: regulation by protein-protein interactions through a double salt bridge. Angew Chem Int Ed Engl 44, 5247–5251 (2005). · DOI
  39. Ho, W. C., Fitzgerald, M. X. & Marmorstein, R. Structure of the p53 core domain dimer bound to DNA. J Biol Chem 281, 20494–20502 (2006). · DOI · Paper page
  40. Khoo, K. H., Andreeva, A. & Fersht, A. R. Adaptive evolution of p53 thermodynamic stability. J Mol Biol 393, 161–175 (2009). · DOI · Paper page
  41. Khoo, K. H., Joerger, A. C., Freund, S. M. & Fersht, A. R. Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core. Protein Eng Des Sel 22, 421–430 (2009). · DOI
  42. Perez, C. A., Ott, J., Mays, D. J. & Pietenpol, J. A. p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm. Oncogene 26, 7363–7370 (2007). · DOI
  43. Schlereth, K., Charles, J. P., Bretz, A. C. & Stiewe, T. Life or death: p53-induced apoptosis requires DNA binding cooperativity. Cell Cycle 9, 4068–4076 (2010). · DOI
  44. Sasaki, Y. et al. The p53 family member genes are involved in the Notch signal pathway. J Biol Chem 277, 719–724 (2002). · DOI · Paper page
  45. Marchenko, N. D., Zaika, A. & Moll, U. M. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 275, 16202–16212 (2000). · DOI · Paper page
  46. Hagn, F. et al. BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J Biol Chem 285, 3439–3450 (2010). · DOI
  47. Leu, J. I., Dumont, P., Hafey, M., Murphy, M. E. & George, D. L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6, 443–450 (2004). · DOI · Paper page
  48. Jiang, P., Du, W., Heese, K. & Wu, M. The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Mol Cell Biol 26, 9071–9082 (2006). · DOI
  49. Mihara, M. et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11, 577–590 (2003). · DOI · Paper page
  50. Sot, B., Freund, S. M. & Fersht, A. R. Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-xL. J Biol Chem 282, 29193–29200 (2007). · DOI
  51. Tomita, Y. et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 281, 8600–8606 (2006). · DOI · Paper page
  52. Petros, A. M., Gunasekera, A., Xu, N., Olejniczak, E. T. & Fesik, S. W. Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBS Lett 559, 171–174 (2004). · DOI
  53. Westfall, M. D., Mays, D. J., Sniezek, J. C. & Pietenpol, J. A. The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 23, 2264–2276 (2003). · DOI · Paper page
  54. Flores, E. R. et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560–564, doi: 10.1038/416560a (2002). · DOI · Paper page
  55. Zdzalik, M. et al. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73. Cell Cycle 9, 4584–4591 (2010). · DOI
  56. Goldstein, I. et al. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 18, 2–11, doi: 10.1038/cgt.2010.63 (2011). · DOI · Paper page
  57. Liefer, K. M. et al. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 60, 4016–4020 (2000).
  58. Celli, J. et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99, 143–153 (1999). · DOI · Paper page
  59. Duijf, P. H. et al. Gain-of-function mutation in ADULT syndrome reveals the presence of a second transactivation domain in p63. Hum Mol Genet 11, 799–804 (2002). · DOI
  60. Sattler, M. et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983–986 (1997). · DOI · Paper page
  61. Privalov, P. L. Stability of proteins: small globular proteins. Adv Protein Chem 33, 167–241 (1979). · DOI · Paper page
  62. Gehring, K. & Ekiel, I. H(C)CH-COSY and (H)CCH-COSY experiments for 13C-labeled proteins in H2O solution. J Magn Reson 135, 185–193 (1998). · doi:10.1006/jmre.1998.1543
  63. Diercks, T. An efficient strategy for assignment of cross-peaks in 3D heteronuclear NOESY experiments. J Biomol NMR 15, 177–180 (1999). · DOI
  64. Cornilescu, G., Delaglio, F. & Bax, A. Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J Biomol NMR 13, 289–302 (1999). · DOI · Paper page
  65. Truffault, V. et al. The solution structure of the N-terminal domain of riboflavin synthase. J Mol Biol 309, 949–960 (2001). · DOI
  66. Coles, M. et al. Common evolutionary origin of swapped-hairpin and double-psi beta barrels. Structure 14, 1489–1498 (2006). · doi:10.1016/j.str.2006.08.005

Cited by

See all 20

Metadata

Authors
Enthart, A., Klein, C., Dehner, A., Coles, M., Gemmecker, G., Kessler, H., & Hagn, F.
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2016-05-26
Volume
6
Issue
1
ISSN
2045-2322
DOI
10.1038/srep26707
Cited by
20
References
5
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.